Skip to main content

Advertisement

Table 2 Type and frequency of KRAS mutations according to smoking status in 80 patients with NSCLC

From: Proportion and clinical features of never-smokers with non-small cell lung cancer

KRAS mutation Nucleotide substitution Amino acid substitution Never-smokers [cases (%)] Ever-smokers [cases (%)] Total [cases (%)]
Transversion GGT>TGT Gly12Cys 6 (22.2) 22 (41.5) 28 (35.0)
  GGT>GTT Gly12Val 7 (25.9) 12 (22.6) 19 (23.8)
  GGT>GCT Gly12Ala 2 (7.4) 3 (5.7) 5 (6.3)
  GGT>TTT Gly12Phe 0 1 (1.9) 1 (1.3)
Transition GGT>GAT Gly12Asp 11 (40.7) 11 (20.8) 22 (27.5)
  GGT>AGT Gly12Ser 0 2 (3.8) 2 (2.5)
  GGC>GAC Gly13Asp 0 2 (3.8) 2 (2.5)
  CAG>CGG Gln22Arg 1 (3.7) 0 1 (1.3)
Total    27 53 80
  1. KRAS Kirsten rat sarcoma viral oncogene homolog, NSCLC non-small cell lung cancer